rasburicase (SR29142)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nutritional and Metabolic Diseases
Conditions
Nutritional and Metabolic Diseases
Trial Timeline
Jun 1, 2005 → Apr 1, 2006
NCT ID
NCT00290992About rasburicase (SR29142)
rasburicase (SR29142) is a phase 2 stage product being developed by Sanofi for Nutritional and Metabolic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00290992. Target conditions include Nutritional and Metabolic Diseases.
What happened to similar drugs?
0 of 1 similar drugs in Nutritional and Metabolic Diseases were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00290992 | Phase 2 | Completed |
| NCT00230217 | Approved | Completed |
| NCT00631579 | Phase 2 | Completed |
| NCT00664144 | Phase 2 | Terminated |
Competing Products
2 competing products in Nutritional and Metabolic Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ClinOleic (Baxter Healthcare, Deerfield, IL, USA) | Baxter | Phase 1 | 22 |
| stannsoporfin | Mallinckrodt Pharmaceuticals | Phase 3 | 30 |